Compare KR & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KR | NTRA |
|---|---|---|
| Founded | 1883 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9B | 32.9B |
| IPO Year | N/A | 2015 |
| Metric | KR | NTRA |
|---|---|---|
| Price | $62.24 | $230.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | $72.54 | ★ $249.53 |
| AVG Volume (30 Days) | ★ 6.7M | 1.1M |
| Earning Date | 03-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $147,225,000,000.00 | $2,116,676,000.00 |
| Revenue This Year | $3.78 | $33.77 |
| Revenue Next Year | $2.10 | $16.92 |
| P/E Ratio | $53.21 | ★ N/A |
| Revenue Growth | N/A | ★ 38.17 |
| 52 Week Low | $58.60 | $125.38 |
| 52 Week High | $74.90 | $256.36 |
| Indicator | KR | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 44.36 |
| Support Level | $61.02 | $229.14 |
| Resistance Level | $62.98 | $250.00 |
| Average True Range (ATR) | 1.54 | 8.22 |
| MACD | 0.04 | -1.40 |
| Stochastic Oscillator | 44.53 | 19.77 |
Kroger is one of the largest grocery retailers in the United States with about 2,700 stores across a portfolio of more than 20 supermarket banners. The company boasts an ingrained presence in US communities, citing that it is a top-two grocer in most of its major market areas. Over one fourth of Kroger's roughly $110 billion in nonperishable and fresh food sales (about 75% of revenue) stems from its private-label portfolio, of which the company manufactures about 30% of units via its own food production plants. The company also operates fuel stations and pharmacies at 60% and 80% of its locations, respectively.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.